On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.
May 9th 2024
An IMID diagnosis or use of immunomodulatory medications were not shown to be a significant risk factor of severe COVID-19 outcomes.
“A Joint Operationâ€: Rheumatologists, Orthopedists Collaborate to Improve Patient Outcomes
With extensive literature review and expert input, the ACR and the American Association of Hip and Knee Surgeons (AAHKS) have come together to propose a set of guidelines for medication during the perioperative period for patients undergoing knee or hip arthroplasty.
Patients May Benefit From Additional Education Following DMARD Prescription
Prescribing rheumatologists discussed drug interactions, costs, contraindications, and severity of side effects with less than 50% of the patients in the study to whom they had prescribed disease-modifying antirheumatic drugs.
Women With Spondyloarthritis Face Increased Risk of Uveitis, Other Conditions
A new study out of Ireland examined the prevalence of extra-articular manifestations in axial spondyloarthritis, and found that women were at significantly higher risk for inflammatory bowel disease and uveitis than men.
Managing Psoriatic Arthritis in Plaque Psoriasis Patients
Nearly one-third of patients with plaque psoriasis will also be diagnosed with psoriatic arthritis. While somewhat common, this diagnosis requires a different approach to care in order to help patients better manage their symptoms.
Study Bolsters Link Between Psoriatic Arthritis and Fibromyalgia
A single-center cross-sectional study has found elevated rates of fibromyalgia in patients with various forms of arthritis, including psoriatic arthritis. It joins previous studies that observed that the two painful conditions sometimes coincide.
Developing New Treatments for Urticaria and Looking Toward the Future
For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.
Testing Ustekinumab for Severe Atopic Dermatitis
October 31st 2016Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.
Diminishing Returns When Switching TNF Treatments in Psoriatic Arthritis
A review of studies concludes that switching psoriatic arthritis patients who have stopped responding to one tumor necrosis factor inhibitor (TNFi) to another will likely reduce their symptoms, but the effectiveness of each new medication will likely be less than each former medication.
Long-Term Secukinumab Treatment Safe and Effective for Patients with Psoriatic Arthritis
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.
Obesity May Exacerbate Psoriatic Arthritis Risks, Limit TNFI Effectiveness
Analysis of patient records from Denmark and Iceland found that obese psoriatic arthritis patients responded less than their lighter counterparts to tumor necrosis factor inhibitors (TNFIs) and that they used such medications for shorter periods of time.
Study Endorses Early TNF Use in Patients with Psoriasis
A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.
Adalimumab: Efficacy and Adverse Effects for Patients with Active Noninfectious Uveitis
The authors say that for uveitis “there is a large unmet medical need" for identifying other therapies. Adalimumab is associated with decreased visual impairment and decreased risk of uveitic flare, but more adverse events, according the results from a recent multinational phase 3 trial.
Trial Shows Ixekizumab Effective Against Psoriatic Arthritis
Ixekizumab patients, who all started with an introductory 160-mg dose, were all more likely than placebo patients to achieve the primary endpoint of the study: a 20% reduction in disease burden as measured by American College of Rheumatology criteria (an ACR20 response) by week 24.
Jerry Bagel: Discussing Treatment Options with Patients
As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.
Jerry Bagel: Approaching Psoriasis Treatment Based on Location
As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.
Jerry Bagel: Research in Eczema Is Lacking, Despite Progress in Psoriasis
Despite the life of a patient with eczema being in many ways similar to that of a patient with psoriasis, their options for treatment are not nearly as robust as the other dermatologic condition.
Jerry Bagel, MD, Explains How to Measure Success in Psoriasis Treatment
As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.
Jerry Bagel, MD: Evolution of Psoriasis Treatment Means Better Results for Patients
As new treatments for plaque psoriasis are developed the field as a whole is taking a new look at the condition. However, there are still challenges to overcome in diagnosis and treatment.
Biosimilar of Enbrel, a Popular Arthritis and Inflammation Drug, Receives FDA Approval
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product†while demonstrating “clinically meaningful differences in terms of safety and effectiveness.â€
Study Shows TNF Inhibitors Prevent Relapse of Uveitis in Most Patients with Ankylosing Spondylitis
Adalimumab, infliximab, and etanercept, reduced the number of uveitis relapses in a retrospective, long-term study of uveitis patients with HLA-B27-positive ankylosing spondylitis who had taken one of these biological agents for at least 1 year.
Study Offers New Treatment Possibilities for Rheumatic Pain Sufferers
Enthesitis refers to the instance of inflammation at the point where a tendon joins to a bone. Looking for further insight into the mechanisms behind inflammatory rheumatism, researchers from delved into the roots of Achilles enthesitis and may have emerged with a new approach to treating many rheumatic conditions.